Noble Financial Has Pessimistic Outlook of UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Noble Financial reduced their Q2 2026 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a note issued to investors on Wednesday, May 13th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings of ($0.77) per share for the quarter, down from their previous forecast of ($0.52). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.44) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at $1.32 EPS, Q4 2026 earnings at $1.44 EPS and FY2026 earnings at $1.46 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

UNCY has been the topic of several other research reports. Wall Street Zen downgraded Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Benchmark reduced their price objective on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a report on Monday, April 6th. B. Riley Financial began coverage on Unicycive Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Finally, Guggenheim reaffirmed a “buy” rating and set a $37.00 price objective (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $8.56 on Friday. The stock’s fifty day moving average price is $7.10 and its two-hundred day moving average price is $6.38. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The company has a market cap of $228.55 million, a price-to-earnings ratio of -3.87 and a beta of 1.78.

Institutional Trading of Unicycive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in UNCY. JPMorgan Chase & Co. raised its position in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics during the 2nd quarter valued at $55,000. Vanguard Group Inc. raised its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $512,000. Finally, Citadel Advisors LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at $182,000. Institutional investors own 40.42% of the company’s stock.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial raised its FY2026 EPS estimate to $1.46 from $0.85 and boosted its Q3 2026 view to $1.32 from $0.79, suggesting improved longer-term profitability expectations.
• Positive Sentiment: HC Wainwright slightly improved its Q2 2026 EPS estimate to ($0.27) from ($0.28), and trimmed its Q4 2026 loss estimate to ($0.03) from ($0.12), indicating a modestly better near-term outlook.
• Positive Sentiment: HC Wainwright also lifted its Q1 2027, Q2 2027, Q3 2027, and Q4 2027 EPS estimates, pointing to stronger profitability later in the forecast period.
• Neutral Sentiment: Analyst reports from HC Wainwright and Noble Financial updated multiple quarterly earnings estimates for UNCY, but the company’s consensus full-year outlook remains a loss at ($1.44) per share.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to ($1.04) from ($0.90), implying a larger expected loss for the current year. HC Wainwright FY2026 estimate cut
• Negative Sentiment: Noble Financial lowered its Q2 2026 EPS estimate to ($0.77) from ($0.52), and HC Wainwright cut its Q3 2026 estimate to ($0.20) from ($0.16), reinforcing some near-term pressure on earnings expectations.
• Negative Sentiment: Separate headlines noted a reduced price target and a “pivots from profit to loss” narrative, which could contribute to bearish sentiment around the stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.